100%, Basel, Fixed-term
The highly competitive Bio-Engineering Systems for Therapeutics (BEST) postdoc program, part of the Next-gen Bioengineers initiative, is run jointly by ETH Zurich and Roche Pharma Research and Early Development (pRED). The program focuses on developing new tools and methods to address challenges in medicine and therapeutic development.
Adeno-associated viruses (AAVs) are the leading platform for gene therapy, yet their clinical potential is often limited by sub-optimal tissue tropism, pre-existing human immunity, and low manufacturing yields. This project aims to develop and deploy state-of-the-art generative models in protein design to enhance AAV manufacturing properties.
Located in Basel, you will have access to world-class facilities at both the Roche and ETH Zurich campuses, fostering a collaborative environment that promotes innovation and research excellence.
Aligned with our values, ETH Zurich encourages an inclusive culture, promoting equality of opportunity, valuing diversity, and nurturing an environment where the rights and dignity of all staff and students are respected. Sustainability is core to our ethos, and we continually strive for a climate-neutral future.
We look forward to engaging with you. Apply online using the form below.
Only applications matching the job profile will be considered.
For inquiries, please reach out to both Prof. Dr. Basile Wicky (basile.wicky@bsse.ethz.ch) and Dr. Denis Phichith (denis.phichith@roche.com).
ETH Zurich is one of the world's leading universities specializing in science and technology. Renowned for excellent education, cutting-edge fundamental research, and the direct transfer of new knowledge into society, ETH attracts over 30,000 individuals from more than 120 countries, fostering an environment that inspires excellence and independent thinking. Located in the heart of Europe and forging global connections, we collaborate to develop solutions for today's and tomorrow's challenges.
Location : Roche
Country : Switzerland